

August 6, 2022

BSE Limited
Department of Corporate Services
Floor 25, Phiroze Jeejeebhoy Towers,
Dalal Street,

Mumbai 400 001

Scrip Code No: 542665

National Stock Exchange of India Limited

Listing Department,

Exchange Plaza,

Bandra Kurla Complex, Bandra (East),

Mumbai - 400 051

Company Symbol: NEOGEN

Dear Sir/Madam,

Sub: Disclosure under regulation 32 of SEBI (Listing Obligations and Disclosure Requirements)
Regulation 2015 ("Listing Regulations")

Ref.: SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019

Pursuant to Regulation 32 of Listing Regulations, we enclose herewith Statement of Deviation / Variation ("Statement") for the quarter ended June 30, 2022, duly reviewed by the Audit Committee at its meeting held on August 6, 2022.

We hereby confirm that there has been no deviation or variation in the use of proceeds of funds raised through issue of Equity Shares on preferential basis.

This intimation is also being uploaded on the Company's website at https://neogenchem.com/announcements/.

Kindly take the above on your record and disseminate the same for the information of investors.

Thanking you, Yours faithfully,

For Neogen Chemicals Limited

Unnati Kanani

Company Secretary & Compliance Officer

Membership No: ACS 35131

Encl: A/a

Registered Office: 1002, Dev Corpora, Cadbury Junction, Eastern Express Highway, Thane (W) 400 601, India.

CIN No. L24200MH1989PLC050919

E:sales@neogenchem.com

W: www.neogenchem.com

T: +91 22 2549 7300

F: +91 22 2549 7399



Quarterly Reporting for Preferential Issue of Equity Shares under Regulation 32 of Listing Regulation.

Statement of Deviation / Variation in utilisation of funds raised

Name of listed entity				Neogen Chemicals Limited				
Mode of Fund Raising			Preferential Issue of Equity Shares					
Date of Raising Funds			06-01-2022					
Amount Raised (Rs. In crores)			225 crores					
Report filed for Quarter ended			30-06-2022					
Monitoring Agency			Not applicable					
Monitoring Agency Name, if applicable			Not Applicable					
Is there a Deviation / Variation in use of funds raised If yes, whether the same is pursuant to change in terms of a contract or			No					
			Not Applicab	ole				
bjects, which was approved by the shareholde	ers							
If Yes, Date of shareholder Approval				ole				
Explanation for the Deviation / Variation Comments of the Audit Committee after review Comments of the auditors, if any Objects for which funds have been raised and where there has been a deviation, in the following table			Not Applicab	Not Applicable				
			Nil					
			Nil See table below					
Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised till 30.06.2022*	Amount of Deviation/Variation for the quarter according to applicable object			
Original Object I) funding the long term growth and expansion of its existing businesses;	Object, if		allocation,	Utilised till	Amount of Deviation/Variation for the quarter according to	Remark		
) funding the long term growth and expansion	Object, if		allocation,	Utilised till	Amount of Deviation/Variation for the quarter according to	Remark		
o) funding the long term growth and expansion of its existing businesses;	Object, if		allocation,	Utilised till	Amount of Deviation/Variation for the quarter according to	Remark		
funding the long term growth and expansion of its existing businesses; financing capital expenditure & working capital requirements;	Object, if any	Allocation	allocation, if any	Utilised till 30.06.2022*	Amount of Deviation/Variation for the quarter according to applicable object	Remark if any		
funding the long term growth and expansion of its existing businesses; b) financing capital expenditure & working capital requirements; b) pre-payment and / or repayment of loans; d) General corporate purpose; and / or e) Any other matters as may be permissible	Object, if any	Allocation	allocation, if any	Utilised till 30.06.2022*	Amount of Deviation/Variation for the quarter according to applicable object	Remark if any		
p) funding the long term growth and expansion of its existing businesses; p) financing capital expenditure & working capital requirements; p) pre-payment and / or repayment of loans; d) General corporate purpose; and / or	Object, if any	Allocation	allocation, if any	Utilised till 30.06.2022*	Amount of Deviation/Variation for the quarter according to applicable object			

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.

~ \ \N		CHEMIC	
Name of Signatory	Ketan Vyas		
Designation	Chief Financial Officer	O THANE	
Date	06-08-2022	111	

^{*}Funds Utilised includes Rs. 7.3 crore on account of issue related expenses

Registered Office: 1002, Dev Corpora, Cadbury Junction,

Eastern Express Highway, Thane (W) 400 601, India.

CIN No. L24200MH1989PLC050919

E: sales@neogenchem.com

W: www.neogenchem.com

T: +91 22 2549 7300

F: +91 22 2549 7399